September 07, 2022

The Evolution of Therapeutic Drug Monitoring for Tacrolimus

Therapeutic drug monitoring is essential with tacrolimus, which is one of the key immunosuppressive agents used after solid organ transplant.

InsightRX’s Jon Faldasz, PharmD BCPS and John Pilla, PharmD discuss the updated consensus report1 on drug-exposure and drug-monitoring recommendations for tacrolimus treatment in Pharmacy Times*. This newest consensus report indicates Bayesian model informed precision dosing tools – like InsightRX Nova – may help to improve pharmacokinetic target attainment of tacrolimus compared with standard TDM. Jon and John also describe the possibility for incorporation of pharmacogenetic information into these pop PK models for additional information in clinical decision support applications.

Click here to read the Pharmacy Times article.

1. Brunet M, van Gelder T, Asberg A, et al. Therapeutic drug monitoring of tacrolimus-personalized therapy: Second consensus report. Ther Drug Monit. 2019;41(3):261-307 doi:10.1097/FTD.0000000000000640

*About Pharmacy Times
Pharmacy Times is a monthly trade journal for pharmacists that provides clinical information for them to use in their everyday practice. Each issue contains articles and features covering pharmacy trends, medication errors, drug interactions, patient education, pharmacy technology, disease state management, patient counseling, product news, pharmacy law, and specialty pharmacy.